文献速递支持与姑息治疗

免疫治疗时代的高突变肿瘤:个体化医疗的典范

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
PubMed 文献 · Eur J Cancer · 2017-08-29

本文综述高突变肿瘤(包括错配修复缺陷(MMRD)和POLE突变癌症)的临床病理与分子特征及免疫环境,讨论免疫治疗在此类肿瘤中的兴起,并评述美国食品药品监督管理局批准程序性细胞死亡1抗体帕博利珠单抗(Keytruda)用于治疗转移性MMRD癌症(不论肿瘤类型)。

要点

  • MMRD肿瘤突变率极高,可形成新抗原,可能增强抗肿瘤免疫应答。
  • POLE催化亚基核酸外切酶域突变的癌症也表现为超突变基因组,可能从免疫治疗中获益。
  • 美国食品药品监督管理局已批准帕博利珠单抗用于治疗转移性MMRD癌症,不论肿瘤类型。

核心结论

  • 美国食品药品监督管理局批准帕博利珠单抗用于治疗转移性MMRD癌症是这些高突变肿瘤管理中的转折点,为更广泛的免疫精准医学策略铺平了道路。

研究设计与样本

  • 本文为综述,概述高突变肿瘤(包括MMRD和POLE突变癌症)的近期数据,聚焦其独特的临床病理和分子特征及免疫环境。

主要发现

  • 免疫检查点抑制剂在多种癌症中显示出前所未有的临床活性,近期在错配修复缺陷(MMRD)肿瘤患者中观察到显著的治疗反应。
  • MMRD癌症突变率极高,可导致新抗原形成,据推测可增强抗肿瘤免疫应答。
  • 除MMRD肿瘤外,DNA聚合酶ε(POLE)催化亚基核酸外切酶域突变的癌症也表现为超突变基因组,因此可能从免疫治疗中获益。

临床怎么用

  • 美国食品药品监督管理局已批准免疫检查点抑制剂程序性细胞死亡1抗体帕博利珠单抗(Keytruda)用于治疗转移性MMRD癌症患者,不论肿瘤类型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors have demonstrated unprecedented clinical activity in a wide range of cancers. Significant therapeutic responses have recently been observed in patients presenting mismatch repair-deficient (MMRD) tumours. MMRD cancers exhibit a remarkably high rate of mutations, which can result in the formation of neoantigens, hypothesised to enhance the antitumour immune response. In addition to MMRD tumours, cancers mutated in the exonuclease domain of the catalytic subunit of the DNA polymerase epsilon (POLE) also exhibit an ultramutated genome and are thus likely to benefit from immunotherapy. In this review, we provide an overview of recent data on hypermutated tumours, including MMRD and POLE-mutated cancers, with a focus on their distinctive clinicopathological and molecular characteristics as well as their immune environment. We also discuss the emergence of immune therapy to treat these hypermutated cancers, and we comment on the recent Food and Drug Administration approval of an immune checkpoint inhibitor, the programmed cell death 1 antibody (pembrolizumab, Keytruda), for the treatment of patients with metastatic MMRD cancers regardless of the tumour type. This breakthrough represents a turning point in the management of these hypermutated tumours and paves the way for broader strategies in immunoprecision medicine.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nebot-Bral L, Brandao D, Verlingue L, et al. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Eur J Cancer. 2017. PMID: 28846956. doi:10.1016/j.ejca.2017.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。